<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404310/" ref="ordinalpos=4874&amp;ncbi_uid=7433472&amp;link_uid=PMC4404310" image-link="/pmc/articles/PMC4404310/figure/F1/" class="imagepopup">Figure 1.  From: Understanding the Biology of CRLF2-Overexpressing Acute Lymphoblastic Leukemia. </a></div><br /><div class="p4l_captionBody">Proposed schema of aberrant signal transduction mediated by the TSLPR heterodimer in CRLF2-overexpressing ALL. JAK/STAT, PI3K, and possibly MAPK signaling networks are hyperactive. Targeting hyperactive signaling nodes with STIs (such as JAK, PI3K pathway, and MEK inhibitors) is a rational therapeutic strategy for preclinical and clinical testing.</div></div>